Blueprint Neurotherapeutic Network (BPN), preclinical neurotherapeutic small molecule development
Dr. Hachicha joined the Division of Translational Research (DTR) in May 2016 as a Scientific Program Manager for the Blueprint Neurotherapeutics Network (BPN). Dr. Hachicha received his Ph.D. in Immunology from Laval University, Canada, and conducted his post-doctoral research at Harvard Medical School in the laboratory of Dr. Charles N. Serhan, investigating the pharmacological role of lipoxins in modulating the inflammatory response in human leucocytes as well as autoimmune and inflammatory disease models. Dr. Hachicha brings to the National Institute of Neurological Disorders and Stroke (NINDS) 18+ years of academic and industry experience (Harvard Medical School, Pharmacopeia, Purdue Pharma, Forest laboratories, Apricus Biosciences, and Institut Pasteur Korea) in drug discovery and development, focused mainly on advancing novel therapeutic modalities ( Small molecules & Biologics) for the treatment of central nervous system disorders (Anxiety, Depression and Pain), autoimmune/inflammatory diseases ( Rheumatoid Arthritis, Asthma and COPD), and solid tumors (Liver cancer and melanoma). Dr. Hachicha managed multi-functional drug discovery and development teams to deliver several drug development candidates. Dr. Hachicha communicates and interacts effectively across multiple drug development functions (Pharmacology, PK- ADME, Medicinal Chemistry, Toxicology, CMC, Clinical, Clinical safety, Medical Affairs and Outcome Research, Regulatory, Business Development and Legal) and exhibits excellent interpersonal skills.